HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology

Context: ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Am J Clin Pathol
Hauptverfasser: Bartley, Angela N., Washington, Mary Kay, Ventura, Christina B., Ismaila, Nofisat, Colasacco, Carol, Benson, Al B., Carrato, Alfredo, Gulley, Margaret L., Jain, Dhanpat, Kakar, Sanjay, Mackay, Helen J., Streutker, Catherine, Tang, Laura, Troxell, Megan, Ajani, Jaffer A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2016
Schlagworte:
Review Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6272805/
https://ncbi.nlm.nih.gov/pubmed/28077399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ajcp/aqw206
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge